OJQ
- Product code
- OJQ
- Device name
- Cardiac Allograft Gene Expression Profiling Test System
- Device class
- Class 2
- 21 CFR
- 21 CFR 862.1163
- Medical specialty
- Cardiovascular
- Marketing pathway
- 510(K)
- 510(k) clearances (last 3 years)
- 1
- Summaries archived here
- 1 (direct download)
- 510(k) clearances (all years, FDA)
- 2 (all years; only the last 3 years are listed here)
FDA classification definition
In vitro diagnostic multivariate index assay (ivdmia) test service, performed in a single laboratory, for assessing the gene expression profile of rna isolated from peripheral blood mononuclear cells (pbmc) and indicated for use to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (acr) at the time of testing in conjunction with standard clinical assessment.
510(k) clearances, last 3 years (1)
| Number | Decision date | Applicant | Device name | Summary |
|---|---|---|---|---|
| K221640 | 2023-09-13 | Caredx, Inc. | AlloMap Heart Molecular Expression Testing |
Official FDA classification page: OJQ
Classification and pathway per current FDA publications. Data from openFDA (CC0).